EnteroMedics (NASDAQ:ETRM) Receives Daily Media Impact Score of 0.14
News coverage about EnteroMedics (NASDAQ:ETRM) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. EnteroMedics earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 47.6873894073614 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- There Are Mixed Technical Signals in EnteroMedics Inc. (ETRM … – StockNewsGazette (stocknewsgazette.com)
- Stock Gaps Down, Monday Overview – BBOX, TGLS, IPWR, GV, OOMA, SGBX, XXII (fxpips.com)
- Alert on oversold position :EnteroMedics Inc. (ETRM) stock RSI moves to 12.48 – Voice Of Analysts (analystsbuzz.com)
- Volume Moving the Tape For Shares of EnteroMedics Inc (ETRM) and Guidance Software Inc (GUID) – Evergreen Caller (evergreencaller.com)
- Traders Alert: Enteromedics Inc (ETRM) – Post Registrar (postregistrar.com)
Shares of EnteroMedics (NASDAQ:ETRM) opened at 1.96 on Tuesday. EnteroMedics has a 52 week low of $1.75 and a 52 week high of $30.41. The firm’s 50-day moving average is $4.27 and its 200 day moving average is $5.31. The firm’s market cap is $13.54 million.
EnteroMedics (NASDAQ:ETRM) last released its quarterly earnings data on Tuesday, August 8th. The medical device company reported ($0.91) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.00) by $0.09. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. EnteroMedics had a negative return on equity of 167.73% and a negative net margin of 4,399.48%. Equities research analysts forecast that EnteroMedics will post ($3.97) EPS for the current year.
ETRM has been the topic of a number of research analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of EnteroMedics in a research note on Wednesday, May 3rd. They issued a “buy” rating and a $11.00 price target on the stock. Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research note on Wednesday, July 12th.
COPYRIGHT VIOLATION NOTICE: “EnteroMedics (NASDAQ:ETRM) Receives Daily Media Impact Score of 0.14” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/15/enteromedics-nasdaqetrm-receives-daily-media-impact-score-of-0-14.html.
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.